KRTL HOLDING GROUP INC. ANNOUNCES STRATEGIC PARTNERSHIP BETWEEN KRTL BIOTECH AND AMNI PHARMACEUTICALS TO ADVANCE INTEGRATED PHARMACEUTICAL PLATFORM

About this update from Krtl Holding Group, Inc

KRTL Holding Group Inc. (“KRTL Holding” or the “Company”) today announced that its wholly owned subsidiary, KRTL Biotech Inc. (“KRTL Biotech”), has entered into a definitive strategic partnership with AMNI Pharmaceuticals Inc. (“AMNI”), establishing a jointly governed pharmaceutical platform designed to integrate manufacturing, distribution, and future development capabilities. The agreement outlines a collaborative framework under which the parties will jointly develop a compliant pharmaceutical infrastructure, including the planned establishment and registration of a 503B outsourcing facility, while emphasizing broader long-term alignment across pharmaceutical development, commercialization, and regulated distribution channels. Strategic Partnership Overview The partnership is structured to leverage the complementary strengths of each organization: KRTL Biotech will contribute regulatory strategy, product development capabilities, and its established FDA engagement framework, including the successful transition of its FDA Establishment Identifier (FEI) alignment to the jointly operated facility. AMNI Pharmaceuticals brings established infrastructure and holds a prescription pharmaceutical wholesale distribution license in the State of Texas, supporting compliant downstream distribution and supply chain operations. Together, the companies intend to create an integrated platform capable of supporting sterile compounding operations, distribution support and future pharmaceutical development capabilities. “This partnership represents a meaningful step in aligning our regulatory strategy with a physical operating platform,” said Cesar Herrera, Chief Executive Officer of KRTL Biotech. “By working alongside AMNI, we are positioning KRTL Biotech to advance its FDA-related infrastructure within a controlled and scalable environment, while also expanding into broader pharmaceutical opportunities.” Facility and Regulatory Alignment As part of the collaboration, operations will be anchored at AMNI’s Texas-based facility, where the parties will establish a jointly governed operating structure. The facility is expected to serve as the central point for regulatory execution, including FDA registration activities and quality system implementation. Importantly, the partnership is designed with a clear regulatory framework that separates manufacturing, distribution, and strategic functions: The jointly formed entity will serve as the FDA-registered outsourcing facility. AMNI will independently operate under its licensed distribution activities. KRTL Biotech will focus on regulatory alignment, development strategy, and commercialization pathways. This structured separation is intended to maintain compliance with FDA requirements while enabling coordinated operational growth. Beyond 503B: Platform for Future Development While the initial phase of the collaboration includes development of a 503B outsourcing facility, the parties emphasized that the broader objective is the creation of a scalable pharmaceutical platform. The agreement provides a foundation to explore additional opportunities as the partnership evolves. The companies noted that any such activities will be pursued in accordance with applicable regulatory requirements and subject to appropriate approvals. “This is not a single-purpose transaction,” added Herrera. “It is a platform-driven partnership designed to support multiple pathways in the pharmaceutical and biotechnology sectors over time.” Governance and Long-Term Alignment The partnership contemplates a jointly owned and governed entity, reflecting equal participation in strategic decision-making and long-term value creation. Both parties will collaborate on operational execution, capital planning, and phased development of the platform. The agreement also establishes a framework for disciplined growth, prioritizing regulatory compliance, quality systems, and inspection readiness as foundational elements of the venture. About KRTL Holding Group Inc. KRTL Holding Group Inc. is focused on advancing innovation across biotechnology, pharmaceuticals, and emerging healthcare platforms through its subsidiaries, including KRTL Biotech Inc. and KRTL International Inc. About KRTL Biotech Inc. KRTL Biotech Inc. is engaged in regulatory strategy, product development, and pharmaceutical commercialization initiatives, with a focus on building compliant and scalable operating platforms aligned with FDA requirements. About AMNI Pharmaceuticals Inc. AMNI Pharmaceuticals Inc. is a Texas-based pharmaceutical company holding applicable state licenses for prescription drug distribution and providing infrastructure to support compliant pharmaceutical operations. For more information: www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.amnipharmaceuticals.com   Forward-Looking Statements This press release contains statements and information that, to the extent that they are not historical fact, may constitute   “forward-looking statements” within the meaning of applicable securities legislation. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments and acquisitions; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company. Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law.

View stock analysis, news, and events for Krtl Holding Group, Inc